Latest Ratios: P/E Ratio -8.5x · EV/EBITDA N/A · ROE -41.0%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $148M | $71M | $72M | $68M | $46M | $258M | — | — | — |
| Enterprise Value | $80M | $3M | $5M | $-20015589 | $-69880897 | $91M | — | — | — |
| P/E Ratio → | -8.54 | — | — | — | — | — | — | — | — |
| P/S Ratio | 19.29 | 9.30 | 694.63 | 3.73 | 4.94 | 25.39 | — | — | — |
| P/B Ratio | 4.20 | 2.02 | 1.42 | 0.96 | 0.55 | 1.65 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.41 | 48.32 | -1.11 | -7.52 | 8.99 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | -797.5% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -279.5% | -279.5% | -34835.4% | -131.0% | -903.1% | -711.2% | -3993.7% | -3993.7% | -1147.1% |
| Net Profit Margin | -229.6% | -229.6% | -32386.4% | -104.6% | -860.6% | -719.2% | -3424.1% | -3602.9% | -974.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -41.0% | -41.0% | -55.2% | -24.7% | -66.7% | -217.9% | — | — | — |
| ROA | -21.0% | -21.0% | -32.6% | -14.1% | -46.8% | -53.5% | -17.3% | -21.6% | -27.0% |
| ROIC | — | — | — | — | — | — | — | — | — |
| ROCE | -41.2% | -41.2% | -53.1% | -26.1% | -65.3% | -63.5% | -23.0% | -26.9% | -39.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 0.18 | 0.37 | 0.32 | 0.34 | 0.05 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.93 | -1.32 | -1.24 | -1.39 | -1.07 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -37.67 | -37.67 | -38.26 | -14.58 | -113.68 | -195.49 | -208.72 | -117.99 | -166.60 |
Net cash position: cash ($75M) exceeds total debt ($6M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.07 | 3.07 | 2.30 | 3.61 | 2.71 | 6.24 | 4.90 | 14.47 | 5.01 |
| Quick Ratio | 3.07 | 3.07 | 2.30 | 3.61 | 2.71 | 6.24 | 4.90 | 14.47 | 5.01 |
| Cash Ratio | 2.96 | 2.96 | 2.23 | 3.49 | 2.61 | 5.85 | 4.65 | 14.00 | 4.74 |
| Asset Turnover | — | 0.10 | 0.00 | 0.16 | 0.06 | 0.05 | 0.01 | 0.00 | 0.03 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 0.83 | 29.39 | 4.47 | 24.33 | 269.27 | 100.68 | 1627.64 | 345.44 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 8.7% | 0.9% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 8.7% | 0.9% | — | — | — |
| Shares Outstanding | — | $38M | $36M | $35M | $35M | $32M | $28M | $35M | $10M |
Clinical and Geopolitical Exposure
Based on current market data, Adagene trades at a P/S ratio of 20.56, a multiple that appears to price in significant platform optionality rather than current clinical-stage revenue, which remains highly erratic and dependent on non-recurring milestone payments from global pharmaceutical partners.
The elevated P/S multiple suggests that investors are valuing the proprietary SAFEbody technology as a scalable engine for future licensing deals rather than evaluating the company on its current, loss-making income statement. This valuation warrants caution, as it implies a high growth expectation that may be disconnected from the reality of the company's current, pre-commercial clinical development cycle.
As reported in recent financial statements, Adagene's gross margin of 96.3% in 2025Q4 is structurally misleading, as it reflects the absence of manufacturing costs for a pre-commercial entity rather than operational efficiency, while the operating margin remains deeply negative at -75.0%.
The high gross margin is a temporary artifact of the company's current licensing-heavy revenue model, which lacks the variable costs associated with commercial-scale biologics production. Investors should monitor the operating margin as the primary indicator of true earning power, as the current -75.0% figure highlights the heavy R&D burden required to advance the ADG126 and ADG106 programs.
According to historical filings, the company's DPO has fluctuated significantly, reaching 1052 days in 2025Q4, which suggests that Adagene is managing its cash outflows by extending payment terms to vendors while navigating the inherent unpredictability of its milestone-driven revenue cycle.
The extreme DPO levels indicate a strategic effort to preserve liquidity by delaying cash outflows, a common practice for clinical-stage firms with limited capital buffers. This reliance on vendor financing may become unsustainable if the company's clinical trial activity scales, potentially creating future liquidity bottlenecks if milestone payments are delayed.
Based on recent SEC filings, Adagene's current ratio of 3.07 indicates a seemingly healthy liquidity position, yet this metric masks the reality of a persistent cash burn that has reduced the company's total cash reserves to $74.5M over the last three years.
While the current ratio suggests an ability to cover short-term obligations, the rapid erosion of the asset base indicates that the company is consuming its capital at a rate that may necessitate further dilutive financing. Investors should view the current liquidity as a finite window that is highly sensitive to the timing of future partnership signatures.
The P/E ratio is fundamentally misapplied to Adagene, as the company's negative earnings and reliance on non-recurring milestone revenue render traditional valuation metrics irrelevant for assessing the intrinsic value of its proprietary antibody engineering platform.
Using P/E to evaluate a pre-commercial biotech firm obscures the value of the underlying intellectual property and clinical pipeline, which are the true drivers of the company's long-term potential. Analysts should instead focus on cash runway, the frequency of new licensing agreements, and clinical data readouts as more appropriate proxies for value creation.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ADAG stock.
Adagene Inc.'s current P/E ratio is -8.5x. This places it at the 50th percentile of its historical range.
Adagene Inc.'s return on equity (ROE) is -41.0%. The historical average is -81.1%.
Based on historical data, Adagene Inc. is trading at a P/E of -8.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Adagene Inc. has 100.0% gross margin and -279.5% operating margin.